Intermittent Regional Therapy with rt-PA is not Superior to Systemic Thrombolysis in Deep Vein Thrombosis (DVT) - a German Multicenter Trial

Summary

In a prospective and randomized multicenter trial the efficacy of intermittent regional and systemic thrombolytic therapy for DVT was evaluated. 137 patients with phlebographically confirmed acute DVT above the calf region were treated with 20 mg of rt-PA for 4 h each day. Thrombolysis was applied either locally via a dorsal pedal vein of the firmly bandaged affected leg or systemically using a cubital vein. Treatment lasted for 4-7 days, and during this time unfractionated heparin was applied continuously with the dosage adjusted according to aPTT (1.5-2.0 times the normal value). A second phlebography was performed within 24 h after the end of treatment. Results were evaluated by an independent radiologist who was unaware of the treatment given

Significant thrombolytic results (e.g. lysis of more than 50% of the original thrombus and complete recanalization of all affected veins) were reached in only 1/3 of all patients. Rates of recanalization did not differ in both groups and bleeding complications occurred in 26.5%. We conclude that intermittent local or systemic application of 20 mg rt-PA seems to be ineffective in the treatment of DVT

• References

• 1 Marder VJ, Sherry S. Thrombolytic therapy: current status (first of two parts). New Engl J Med 1988; 318: 1512-1520
• 2 Marder VJ, Sherry S. Thrombolytic therapy: current status (second of two parts). New Engl J Med 1988; 318: 1585-1595
• 3 Brown WD, Goldhaber SZ. How to select patients with deep vein thrombosis for tPA therapy. Chest 1989; 95: 276S-278S
• 4 Goldhaber SZ. Thrombolysis in venous thromboembolism. An international perspective Chest 1990; 97: 176S-181S
• 5 Grimm W, Schwieder G, Wagner T. Comparison of results of fibrinolytic therapy with urokinase, ultra high dose streptokinase and recombinant tissue type plasminogen activator in deep vein thrombosis. Blood 1990; 131-137
• 6 Wagner T. Stellenwert der Thrombolyse-Therapie bei tiefen Venen-thrombosen. Z gesamte Inn Med 1993; 48: 324-331
• 7 Eichlisberger R, Frauchiger B, Widmer MTh, Widmer LK, Jäger K. Spätfolgen der tiefen Venenthrombose: ein 13-Jahres-follow-up von 223 Patienten. Vasa 1994; 23: 234-243
• 8 Thiery L. What is the medical, social, and economic impact of chronic venous insufficiency (CVI). Medicographia 1994; 16: 7-11
• 9 O’Meara III JJ, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330: 1864-1869
• 10 Agnelli G, Buchanan MR, Fernandez F, Boneu B, Van Ryn J, Hirsh J, Collen D. A Comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985; 72: 178-182
• 11 Collen D, Lijnen HR. Tissue-type plasminogen activator. Mechanism of action and thrombolytic properties Haemostasis 1986; 16: 25-32
• 12 Agnelli G, Hirsh J. Optimal dosage regimens of tissue-type plasminogen activator. Sem Thromb Haemost 1987; 13: 160-162
• 13 Losealzo BraunwaldE. Tissue plasminogen activator. New Engl J Med 1988; 319: 925-931
• 14 Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, Sobel M, Wheeler HB, Plante D, Kim H, Hopkins A, Tufte M, Stump D, Braunwald E. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88: 235-240
• 15 Zimmermann R, Gürsoy A, Horn A, Harenberg DiehmC, Kübler W. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator. Sem Thromb Haemost 1991; 17: 48-54
• 16 Zimmermann R, Seifried W, Schramm W, Haarmann E, Bluhmki E. rt-PA thrombolysis of deep vein thrombosis with different dosages. Results of a prospective multicenter study Thromb Haemost 1991; 65 (06) 1132
• 17 Pilger E, Obernosterer A, Decrinis M, Aschauer S, Doder S, Lafer M, Tischler R, Stark G. Pilot trial of recombinant tissue type plasminogen activator in deep venous thrombosis. Fibrinolysis 1992; 6: 148
• 18 Levine MN, Weitz J, Turpie AG G, Anrew M, Cruickshank M, Hirsh J. A new hhort infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. Chest 1990; 97: 168S-171S
• 19 Heimig Th, Marlin M. Lyseblock-Technik – Eine neue lokale Be-handlungsform von Unterschenkelvenen- und Arterienverschlüssen. Vasa 1992; 21: 289-293
• 20 Mumme A, Ernst R, Kemen M, Walterbusch G, Zumtobel V. Regional hypertherme Fibrinolytika-Perfusion bei postoperativcr tiefer Venenthrombose. Dtseh mod Wschr 1992; 117: 1637-1642
• 21 Mumme A, Kemen M, Homaim HH, Zumtobel V. Temperatur-abhängigkeil der Fibrinolyse mil Streptokinase. Dtseh med Wschr 1993; 118: 1594-1596
• 22 Martin M, Fiebach BJ O. Die Streplokinase-Behandlung peripherer Arterien- und Venenversehlüsse unter besonderer Berücksiehtigung der ultrahohen Dosierung. Verlag Hans Huber; Bern: 1985
• 23 Theiss W, Baumann G, Klein G. Fibrinolytische Behandlung tiefer Venenthrombosen mit Streptokinase in ultrahoher Dosierung. Dtsch med Wschr 1987; 112: 668-674
• 24 Podlaha R, Sehliehling P. Erfahrungen mit Streptokinase in ultrahoher Dosierung bei der Behandlung der tiefen Beinvenenthrom-bose. Phlebol Proktol 1988; 17: 197-201
• 25 Zinnagl N. Erfahrungen mit der Fibrinolyse mittels Streptokinase in konventioneller und ultrahoher Dosierung. Phlebol Proktol 1988; 17: 220-222
• 26 Martin M, Fiebach BJ O. Short-term ultrahigh streptokinase treatment of chronic arterial occlusions and acute deep vein thrombosis. Sem Thromb Haemost 1991; 117: 21-38
• 27 Grimm W, Schwieder G, Wagner T. Fibrinolytische Therapie defer Venenlhrombosen mit Urokinase, ultrahochdosierter Streptokinase und rekombinantem Gewebsplasminogenaktivator. Med Welt 1995; 46: 150-155
• 28 Cossio JA J, Ortin PM, Riera L, Reparaz L. Erprobung einer neuen Methode in der lokoregionalen Behandlung mit Urokinase bei liefer Venenthrombose (TVT). Phlebol 1992; 21: 119-122
• 29 Timmermann J, Rudofsky G, Hagg N, Ranft J, Ruch U. Lokale fibrinolytische Therapie (PLL) der tiefen Beinvenenthrombose mit rt-PA. Phlebol 1992; 21: 205-209
• 30 Brandt H, Snedecor GW. Chi-Quadrat-Test In: Angewandte Statistik. Sachs L. ed. Springer Verlag; Berlin, Heidelberg, New York; 1974. pp 357-361
• 31 Sokal RR, Rohlf FJ. Test auf Gleichheit zweier Prozentsätze. In: Biometric. Sokal RR, Rohlf FJ. eds. WH Freeman and Company; San Francisco: 1969. pp 607-608
• 32 Thiele C, Theiss W, Kurfürst-Seebauer R. Langzeitergebnisse nach fibrinolytischer Behandlung tiefer Venenlhrombosen im Becken-Bein-Bereich. Vasa 1989; 18: 48-55
• 33 Obernosterer A, Decrinis N, Pilger E. Inzidenz eines postthromboti-schen Syndroms nach systemischer Fibrinolyse von tiefen Venen-thrombosen. In: Angiologie 91. Rudofsky E, Pilger E, Jager K. eds. Vasa. 1991; Suppl. 33: 120
• 34 Bounameaux H, Banga JD, Bluhmki E, Coccheri S, Fiessinger JN, Haarmann W, Lockner D, Mahler F, Ninet J, Schneider PA, de Tor-rente A, van der Meer J, Verhaeghe R. Double-blind, randomized comparison of systemic infusion of 0,25 versus 0,50 mg/kg/24 h of alte-plase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: Results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) Trial. Thromb Haemost 1992; 67: 306-309
• 35 Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep venous thrombosis – Follow-up results of a prospective study. Acta Med Scand 1982; 211: 65
• 36 Widmer LK, Zemp E, Widmer MT h, Schmitt HE, Brandenberg E, Voelin R, Biland L, da Silva A, Maggs M. Late results in deep venous thrombosis of the lower extremity. Vasa 1985; 14: 264
• 37 Widmer MT h, Madar G, Widmer LK. Incidence of postthrombotic syndrome – Follow-up on 99 patients with deep venous thrombosis and thrombolytic or heparin treatment. In: New Concepts in Streptokinase Dosimetry. Martin M, Schoop W, Hirsch J. eds. Verlag Hans Huber; Bern/Stuttgart/Wien: 1978